Table 2.

Baseline patient features

Factor	Result (median or rate)
Age (years)	64 [IQR: 58–72]
Age >65 years	28/45 (61%)
Gender (M/F)	30/14
C-reactive protein (mg/dL)	5 [IQR: 2–8]
Albumin (g/dL)	3.5 [IQR: 3.1–3.9]
CEA level (ng/dL)	4 [2–6]
Neutrophil-to-lymphocyte ratio	2.2 [IQR: 1.4-3-1]
Neutrophil-to-lymphocyte ratio (>3)	9/44 (20.4%)
Modified Glasgow Prognostic Score (0–1-2)	32/7/5
Primary tumor T status (1–2 vs. 3–4)	8/36
Primary tumor N status (0 vs. 1–2)	16/28
Active smoking habit	14/44 (31%)
Adjuvant chemotherapy*	40/44 (90%)
Central vs. peripheral metastasis	14/30
Metastasis size >3 cm	12/44 (27%)
Single versus multiple metastasis	22/22
Number of metastasis	1.5 [IQR: 1–2]
Disease-free interval (months)	26 [IQR: 14–38]

CEA, carcino-embryonic antigen; IQR, interquartile range.